Immunosuppressant drugs - The role of therapeutic drug monitoring

British Journal of Clinical Pharmacology

Volumn 52, Issue SUPPL. 1, 2001, Pages 61-73

  Johnston, Atholl ^a   Holt, David W ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; S6 KINASE; STEROID; TACROLIMUS; THIOPURINE METHYLTRANSFERASE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUALITY CONTROL; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION;

EID: 0034839030     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2001.00365.x     Document Type: Article

References (164)

1. Therapeutic drug monitoring
2. Neoral absorption profiling: An evolution in effectiveness
3. Cyclosporin monitoring: Its role in autoimmune indications
4. Monitoring new immunosuppressive agents. Are the methods adequate?
5. The present position and future prospects of organ transplantation
6. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation
7. Should 6-thioguanine nucleotides be monitored in heart transplant recipients given azathioprine?
8. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity
9. Isolation of a human thipurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans
10. Monitoring of TPMT in heart transplant recipients under immunosuppressive therapy with azathioprine
11. Therapeutic drug monitoring of cytotoxic drugs
12. Muromonab CD3: A reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection
13. Ten years of Orthoclone OKT3 (muromonab-CD3): A review
14. OKT3 serum levels as a guide for prophylactic therapy: A pilot study in kidney transplant recipients
15. New insights into therapy with monoclonal antibodies in allograft transplantation
16. OKT3 prophylaxis in kidney transplant recipients: Drug monitoring by flow cytometry
17. Organ transplantation. The present position and future prospects of organ transplantation
18. Immunosuppression and clinical organ transplantation
19. Influence of treatment with cyclosporine, azathioprine and steroids on chronic allograft failure
20. Biological effects of cyclosporin A. A new antilymphocytic agent
21. The discovery and development of cyclosporine (Sandimmune)
22. Reduced cyclosporine absorption preceded acute allograft rejection in a child with a liver transplant
23. The history of cyclosporin A (Sandimmune) revisited: Another point of view
24. Toxic effects of immunosuppressive drugs: Mechanisms and strategies for controlling them
25. The influence of haematocrit on blood cyclosporin measurements in vivo
26. Sample pretreatment to minimize interference from whole blood in the radioimmunoassay for cyclosporine
27. Measurement of cyclosporine: Methodological problems
28. The United Kingdom Cyclosporin Quality Assessment Scheme
29. Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine
30. Blood cyclosporin concentrations and renal allograft dysfunction
31. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine
32. Canadian Consensus Meeting on cyclosporine monitoring: Report of the consensus panel
33. Optimizing the use of cyclosporine in renal transplantation
34. Cyclosporin assay techniques. Accuracy and reproducibility variables impacting on measurements
35. Methodological and clinical aspects of cyclosporin monitoring: Report of the Association of Clinical Biochemists task force
36. Changing stable heart transplant recipients from Sandimmune to Neoral
37. Sandimmun neoral pharmacokinetics: Impact of the new oral formulation
38. The pharmacokinetics of Sandimmun Neoral: A new oral formulation of cyclosporine
39. Accuracy of cyclosporin measurements made in capillary blood samples obtained by skin puncture
40. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
41. Cyclosporin monitoring: Trough or AUC?
42. Cyclosporin Microemulsion. A guide to usage and monitoring
43. A limited sampling strategy for the measurement of cyclosporine AUC
44. Predicting patients' exposure to cyclosporin
45. Cyclosporine plasma levels six hours after oral administration. A useful tool for monitoring therapy
46. Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients
47. Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis
48. Cyclosporine dose adjustment using levels obtained six hours after the morning dose: Effect on side effects in patients with autoimmune diseases
49. Optimization of cyclosporin therapy with new therapeutic drug monitoring strategies: Report from the international Neoral TDM advisory consensus meeting (Vancouver, November 1997)
50. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients
51. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: Results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8)
52. Neoral in liver transplantation
53. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients
54. Two-hour cyclosporin concentration (C2) as a monitoring tool for Neoral
55. Pharmacokinetic validation of neoral absorption profiling
56. The temporal profile of calcineurin inhibition by cyclosporine in vivo
57. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen
58. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients
59. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients
60. Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction
61. Consensus document: Therapeutic monitoring of tacrolimus (FK-506)
62. Therapeutic drug monitoring of tacrolimus in clinical transplantation
63. Clinical pharmacokinetics of tacrolimus
64. Japanese study of FK 506 on kidney transplantation: The benefit of monitoring the whole blood FK 506 concentration
65. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants
66. An abbreviated area-under-the-curve monitoring for tacrolimus patients with liver transplants
67. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus
68. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients
69. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients - Importance of trough level as a practical indicator
70. Mycophenolate mofetil
71. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review
72. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil
73. Mycophenolate mofetil for transplantation: New drug, old problems?
74. Therapeutic drug monitoring of mycophenolic acid: Comparison of HPLC and immunoassay reveals new MPA metabolites
75. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
76. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
77. Mycophenolic acid (NSC-129185): Preliminary clinical trials
78. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin, corticosteroids for prevention of acute rejection
79. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
80. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
81. Clinical pharmacokinetics of mycophenolate mofetil
82. Opportunities for therapeutic drug monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection
83. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation
84. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid
85. Mycophenolate mofetil dose adjustment based on trough levels improves outcome after heart transplantion
86. Therapeutic monitoring of mycophenolic acid. A consensus panel report
87. Current opinions on therapeutic drug monitoring of immunosuppressive drugs
88. Mycophenolate mofetil-based, cyclosporin-free induction and maintenance immunosuppression
89. Sirolimus-tacrolimus combination immunosuppression
90. Sirolimus (rapamycin) -based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
91. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
92. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial
93. An immunoassay for the measurement of sirolimus
94. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection
95. A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection
96. The IL-2 receptor complex: Its structure, function, and target genes
97. The IL-2/IL-2 receptor system: A current overview
98. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation
99. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
100. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation
101. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
102. Development of Zenapax: A humanized anti-tac antibody
103. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients
104. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts
105. Disposition and immunodynamics of basiliximab in liver allograft recipients
106. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel
107. Cyclosporin A: Analytical methodology and factors affecting therapeutic drug monitoring
108. Cyclosporine A: Clinical experience and therapeutic drug monitoring
109. A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity
110. Target concentration strategy for cyclosporin monitoring
111. Total testing process applied to therapeutic drug monitoring: Impact on patients' outcomes and economics
112. Bayesian and threshold probabilities in therapeutic drug monitoring: When can serum drug concentrations alter clinical decisions?
113. How to measure cyclosporin
114. Quality assurance for cyclosporin assays in body fluids
115. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation
116. Calibration of the CYCLO-Trac SP cyclosporine radioimmunoassay
117. Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach
118. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): A critical overview of performance characteristics and comparison with HPLC
119. Improved therapeutic drug monitoring of tacrolimus (FK506) by tandem mass spectrometry
120. Limit of quantitation (Functional Sensitivity) of the new IMx Tacrolimus II microparticulate immunoassay
121. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
122. Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection
123. Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs
124. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure
125. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay
126. Evaluation of the EMIT Mycophenolic Acid Assay from Dade Behring
127. The International Mycophenolic Acid Proficiency Testing Scheme
128. External quality assessment scheme for cyclosporin in body fluids
129. Tacrolimus quality assessment
130. Quality assessment issues of new immunosuppressive drugs and experimental experience
131. Proficiency testing issues relating to sirolimus
132. Monitoring immunosuppressive drugs: The rational for proficiency testing
133. Immunological monitoring of azathioprine treatment in multiple sclerosis patients
134. Randomized trial of blood eosinophil count monitoring as a guide to corticosteroid dosage adjustment after heart transplantation
135. Association between blood eosinophil counts and acute cardiac and pulmonary allograft rejection
136. Modes of action of FK506, cyclosporin A and rapamycin
137. The mechanism of action of cyclosporin A and FK506
138. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation
139. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients
140. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: Role of deoxyguanosine nucleotide depletion
141. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients
142. Pharmacodynamic monitoring of immunosuppressive drugs
143. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases
144. P70 S6 kinase assay. A pharmacodynamic monitoring strategy for rapamycin; Assay development
145. Monitoring antithymocyte globulin in renal transplantation
146. Drug policy 1996
147. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?
148. Use of therapeutic drug monitoring in pharmacoeconomics
149. Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring
150. Concentration-controlled trials. What does the future hold?
151. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 Kidney Transplant Group
152. The pharmacokinetic/pharmacodynamic relationship for MPA in renal transplantation - Results of a randomised concentration - controlled trial (RCCT) of MMF
153. Immunosuppressive protocols for renal transplantation
154. Generic substitution for cyclosporine: What should we be looking for in a new formulation
155. Oral administration of liposomes containing cyclosporine: A pharmacokinetic study
156. Preclinical evaluation of a new immunosuppressive agent, FTY720
157. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo
158. Xenotransplantation: Problems and prospects
159. Multicenter evaluation of the new CEDIA CsA Plus assay for whole blood cyclosporine